Shilpa Medicare slips after USFDA issues 10 observations

The stock slipped 6% to Rs 599 on the BSE in intra-day trade.

medicine, drug, antibiotic, doctor, pharmaceuticals
SI Reporter Mumbai
Last Updated : Dec 06 2017 | 1:48 PM IST
Shilpa Medicare slipped 6% to Rs 599 on the BSE in intra-day trade after the company announced that it has received ten 483 observations from the US drug regulator in relation to SEZ formulation facilities located at Telangana.

“The company has received 483 Observations from the United States Food & Drug Administration (USFDA) in relation to SEZ Formulation Facilities situated at Jadcherla, Telangana (near Hyderabad),” Shilpa Medicare said in a statement.

Total 10 observations were cited during the close up meeting. Of these 7 observations are improvement in procedures and practices, while 3 observations are related to setting of analytical specifications, test procedures and method validation, it added.

At 01:37 PM; the stock was trading 4% lower at Rs 609 as compared to 0.44% decline in the S&P BSE Sensex. A combined 191,781 shares changed hands on the counter on the NSE and BSE so far.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story